Literature DB >> 27672551

Use of Fungal Diagnostics and Therapy in Pediatric Cancer Patients in Resource-Limited Settings.

Sheena Mukkada1, Jeannette Kirby2, Nopporn Apiwattanakul3, Randall T Hayden4, Miguela A Caniza5.   

Abstract

Fungal diseases are an important cause of mortality in immunocompromised hosts, and their incidence in pediatric cancer patients in low- to middle-income countries is underestimated. In this review, we present relevant, up-to-date information about the most common opportunistic and endemic fungal diseases among children with cancer, their geographic distribution, and recommended diagnostics and treatment. Efforts to improve the care of children with cancer and fungal disease must address the urgent need for sustainable and cost-effective solutions that improve training, fungal disease testing capability, and the use of available resources. We hope that the collective information presented here will be used to advise healthcare providers, regional and country health leaders, and policymakers of the current challenges in diagnosing and treating fungal infections in children with cancer in low- to middle-income countries.

Entities:  

Keywords:  antifungals; fungal biomarkers; fungus; low- to middle-income countries; pediatric; resource-limited settings.

Year:  2016        PMID: 27672551      PMCID: PMC5034939          DOI: 10.1007/s40588-016-0038-2

Source DB:  PubMed          Journal:  Curr Clin Microbiol Rep        ISSN: 2196-5471


  125 in total

Review 1.  Diagnosis of invasive fungal infections in hematology and oncology--guidelines from the Infectious Diseases Working Party in Haematology and Oncology of the German Society for Haematology and Oncology (AGIHO).

Authors:  M Ruhnke; A Böhme; D Buchheidt; O Cornely; K Donhuijsen; H Einsele; R Enzensberger; H Hebart; C P Heussel; M Horger; H Hof; M Karthaus; W Krüger; G Maschmeyer; O Penack; J Ritter; S Schwartz
Journal:  Ann Oncol       Date:  2011-09-23       Impact factor: 32.976

2.  Neonatal candidiasis: epidemiology, risk factors, and clinical judgment.

Authors:  Daniel K Benjamin; Barbara J Stoll; Marie G Gantz; Michele C Walsh; Pablo J Sánchez; Abhik Das; Seetha Shankaran; Rosemary D Higgins; Kathy J Auten; Nancy A Miller; Thomas J Walsh; Abbot R Laptook; Waldemar A Carlo; Kathleen A Kennedy; Neil N Finer; Shahnaz Duara; Kurt Schibler; Rachel L Chapman; Krisa P Van Meurs; Ivan D Frantz; Dale L Phelps; Brenda B Poindexter; Edward F Bell; T Michael O'Shea; Kristi L Watterberg; Ronald N Goldberg
Journal:  Pediatrics       Date:  2010-09-27       Impact factor: 7.124

3.  Paracoccidioidomycosis in Mexico: clinical and epidemiological data from 93 new cases (1972-2012).

Authors:  Rubén López-Martínez; Francisca Hernández-Hernández; Luis Javier Méndez-Tovar; Patricia Manzano-Gayosso; Alexandro Bonifaz; Roberto Arenas; María Del Carmen Padilla-Desgarennes; Roberto Estrada; Guadalupe Chávez
Journal:  Mycoses       Date:  2014-04-02       Impact factor: 4.377

4.  Candida speciation, antifungal treatment and adverse events in pediatric invasive candidiasis: results from 441 infections in a prospective, multi-national study.

Authors:  Debra L Palazzi; Antonio Arrieta; Elio Castagnola; Natasha Halasa; Sydney Hubbard; Ava A Brozovich; Brian T Fisher; William J Steinbach
Journal:  Pediatr Infect Dis J       Date:  2014-12       Impact factor: 2.129

5.  Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America.

Authors:  Stanley W Chapman; William E Dismukes; Laurie A Proia; Robert W Bradsher; Peter G Pappas; Michael G Threlkeld; Carol A Kauffman
Journal:  Clin Infect Dis       Date:  2008-06-15       Impact factor: 9.079

6.  Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group.

Authors:  Ben De Pauw; Thomas J Walsh; J Peter Donnelly; David A Stevens; John E Edwards; Thierry Calandra; Peter G Pappas; Johan Maertens; Olivier Lortholary; Carol A Kauffman; David W Denning; Thomas F Patterson; Georg Maschmeyer; Jacques Bille; William E Dismukes; Raoul Herbrecht; William W Hope; Christopher C Kibbler; Bart Jan Kullberg; Kieren A Marr; Patricia Muñoz; Frank C Odds; John R Perfect; Angela Restrepo; Markus Ruhnke; Brahm H Segal; Jack D Sobel; Tania C Sorrell; Claudio Viscoli; John R Wingard; Theoklis Zaoutis; John E Bennett
Journal:  Clin Infect Dis       Date:  2008-06-15       Impact factor: 9.079

7.  Performance of serum biomarkers for the early detection of invasive aspergillosis in febrile, neutropenic patients: a multi-state model.

Authors:  Michaël Schwarzinger; Luis Sagaon-Teyssier; Odile Cabaret; Stéphane Bretagne; Catherine Cordonnier
Journal:  PLoS One       Date:  2013-06-14       Impact factor: 3.240

Review 8.  Aspergillus Polymerase Chain Reaction: Systematic Review of Evidence for Clinical Use in Comparison With Antigen Testing.

Authors:  P Lewis White; John R Wingard; Stéphane Bretagne; Jürgen Löffler; Thomas F Patterson; Monica A Slavin; Rosemary A Barnes; Peter G Pappas; J Peter Donnelly
Journal:  Clin Infect Dis       Date:  2015-06-25       Impact factor: 9.079

Review 9.  Epidemiology and risk factors for invasive candidiasis.

Authors:  Nur Yapar
Journal:  Ther Clin Risk Manag       Date:  2014-02-13       Impact factor: 2.423

10.  Epidemiology and Microbiologic Characterization of Nosocomial Candidemia from a Brazilian National Surveillance Program.

Authors:  André Mario Doi; Antonio Carlos Campos Pignatari; Michael B Edmond; Alexandre Rodrigues Marra; Luis Fernando Aranha Camargo; Ricardo Andreotti Siqueira; Vivian Pereira da Mota; Arnaldo Lopes Colombo
Journal:  PLoS One       Date:  2016-01-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.